American Reprographics Company (NYSE: ARC) was upgraded by analysts at Sidoti from a “neutral” rating to a “buy” rating. Shares in ARC are up 25.64% over the last 3 months.
ARC, a reprographics company, provides business-to-business document management services. ARC offers various services, such as document management that include storing, tracking, and providing authorized access to documents; document distribution and logistics, which involves in transferring digital documents throughout local and wide-area computer networks, and over the Internet, as well as the pickup, delivery, and shipping of hardcopy documents; print-on-demand services; and on-site services, such as placing equipment and staff in customers’ location to provide printing and other reprographics services.
ARC also sells reprographics equipment and supplies, as well as licenses reprographics technology products to independent reprographers. It serves architectural, engineering, and construction industries, as well as aerospace, technology, financial services, retail, entertainment, and food and hospitality industries. ARC operates 239 reprographics service centers comprising 225 in the United States, 7 in Canada, 4 in China, 2 in India, and 1 in the United Kingdom.
Flow (NASDAQ: FLOW) was upgraded by analysts at Northland Securities from a “market perform” rating to an “outperform” rating. The analysts now have a $4.00 price target on the stock, up previously from $3.50. Shares in FLOW were up 36.15% last week.
FLOW, together with its subsidiaries, operates as a technology-based company providing waterjet cutting, surface preparation, and cleaning solutions in the United States, Europe, Asia, and internationally. FLOW’s products include ultrahigh-pressure water pumps and power waterjet systems used to cut and clean materials.
FLOW also offers ultrahigh-pressure surface preparation and industrial cleaning systems used in waterjet cleaning for coating removal; and consumable parts used by the pump and cutting heads during operations, such as seals and orifices, as well as provides related services. FLOW sells its consumable parts online through flowparts.com in the United States and floweuropeparts.com in Europe. FLOW offers its products to various end-user applications and industries, including automotive, aerospace, paper, job shop, and stone and tile industries.
Smith & Wesson (NASDAQ: SWHC) was upgraded by analysts at CL King to a “buy” rating. Shares in SWHC were up 29.49% last week.
SWHC provides products and services for safety, security, protection, and sports in the United States and internationally. The company offers firearms, handguns, sporting rifles, hunting rifles, black powder firearms, handcuffs, and firearm-related products and accessories. It also provides turnkey perimeter security solutions to protect and control access to key military, government, and corporate facilities.
SWHC’s perimeter security solutions include proprietary products, such as canopies and guard booths, signs and signals, intrusion detection systems and vehicle inspection systems, fencing and gates, and bollards and wedge barriers to reduced-risk and mobile barriers, as well as facility analysis, solution design, system engineering and installation, construction management, customer training, and system maintenance. In addition, it offers forging, heat treating, finishing, and plating services.
SWHC sells its products to gun enthusiasts, collectors, hunters, sportsmen, competitive shooters, individuals desiring home and personal protection, law enforcement and security agencies and officers, and military agencies primarily through distributors, dealers, consumer promotions, and retailers.
SWHC also operates Websites; and a retail store, including a commercial shooting range, in Springfield, Massachusetts, as well as an online retail store for non-firearm accessories to market its products and services.
MEMC Electronic Materials Inc (NYSE: WFR) was upgraded by analysts at Collins Stewart from a “neutral” rating to a “buy” rating. The analysts now have a $5.50 price target on the stock. Shares in MEMC are down 49.54% for the last 6 months.
MEMC Electronic Materials, Inc. engages in the development, manufacture, and sale of silicon wafers for the semiconductor industry worldwide. Its wafers are used as the starting material for the manufacture of various types of semiconductor devices, including microprocessor, memory, logic, and power devices.
MEMC operates in three segments: Semiconductor Materials, Solar Materials, and Solar Energy.
The Semiconductor Materials segment offers prime polished wafers, such as OPTIA and annealed products; epitaxial wafers consisting of thin silicon layer grown on the polished surface of the wafer; test/monitor wafers for testing semiconductor fabrication lines and processes; and silicon-on-insulator wafers used in the chip making process.
The Solar Materials segment provides solar wafers that are used as the starting material for crystalline solar cells.
The Solar Energy segment offers solar energy services that integrate the design, installation, financing, monitoring, operations, and maintenance portions of the downstream solar market.
As of December 31, 2010, MEMC interconnected approximately 393 solar power system systems representing 267 megawatt of solar energy generating capacity. In addition, the company develops and sells photovoltaic energy solutions. Its customers comprise semiconductor device manufacturers, including the memory, microprocessor, and ASIC manufacturers; and foundries, solar cell and module manufacturers, and flat panel display producers and other industries. MEMC also serves commercial customers, such as national retail chains and real estate property management firms; federal, state, and municipal governments; and utilities.
MEMC markets its solar energy generation, monitoring, and maintenance services through a direct sales force, as well as through solar channel partners.
Pluristem Therapeutics (NASDAQ: PSTI) is now covered by analysts at Global Hunter Securities. The analysts set a “buy” rating and a $5.00 price target on the stock. Shares in PSTI are down 9.82$ over the last month.
PSTI, a bio-therapeutic company, engages in the research, development, and commercialization of standardized cell therapy products for the treatment of life threatening diseases. PSTI’s products are derived from human placenta, a non-controversial, non-embryonic, adult cell source. Its Placental adherent stromal cells are grown in the company’s proprietary PluriX three-dimensional process that allows cells to grow in a natural environment.
PSTI provides PLX-PAD that has completed Phase I clinical trials for people suffering from peripheral artery disease. It also offers various product candidates for diabetic foot ulcers, adjuvant hip replacement surgery, athletic injuries, inflammatory bowel disease, multiple sclerosis, neuropathic pain, ischemic stroke, adjuvant for UCB transplantation, and radiation exposure.
Sirius XM Radio Inc. (NASDAQ: SIRI) is now covered by analysts at Citigroup. The analysts set a “buy” rating and a $2.20 price target on the stock. Shares in SIRI were down 6.17% last week.
SIRI provides satellite radio services in the United States and Canada. SIRI broadcasts a programming lineup of approximately 135 channels of commercial-free music, sports, news and information, talk and entertainment, traffic, and weather on subscription fee basis through two satellite radio systems in the United States; and holds an interest in the satellite radio services offered in Canada.
SIRI also simulcasts music and selected non-music channels over the Internet; and offers applications to allow consumers to access its Internet services on mobile devices.
As of December 31, 2010, SIRI had 20,190,964 subscribers. In addition, SIRI designs, establishes specifications, sources or specifies parts and components, and manages various aspects of the logistics and production of satellite radios; licenses its technology to various electronics manufacturers to develop, manufacture, and distribute radios under various brands; and imports radios distributed through its Websites.
SIRI’s satellite radios are primarily distributed through automakers, retailers, and its Websites. Further, SIRI provides music services for commercial establishments; a satellite television service to offer music channels as part of certain programming packages on the DISH Network satellite television service; music and comedy channels to mobile phone users through mobile phone carriers; Backseat TV, a service offering television content designed primarily for children in the backseat of vehicles; Travel Link, a suite of data services that include graphical weather, fuel prices, sports schedules and scores, and movie listings; and real-time traffic and weather services.
Synergetics Usa Incorporated (NASDAQ: SURG) is now covered by analysts at Wunderlich. The analysts set a “buy” rating and a $8.00 price target on the stock. Shares in SURG were up 6.69% on Friday.
SURG, a medical device company, engages in the design, manufacture, and marketing of microsurgical instruments and consumables primarily for ophthalmology and neurosurgery markets in the United States and internationally. SURG’s product lines focus upon precision engineered, microsurgical, handheld devices, and the microscopic delivery of laser energy, ultrasound, electrosurgery, aspiration, illumination and irrigation that are delivered in multiple combinations. SURG offers retinal surgical items, including handheld disposable and reusable forceps and scissors, fiberoptics for illumination and photocoagulation, cannulas, scrapers, and other reusable and disposable surgical devices.
SURG also provides bipolar electrosurgical generators; lesion generators used for minimally invasive pain treatment; and directional laser probes, as well as offers gauge instrumentation to the vitreoretinal surgical market. SURG sells its products through direct sales employees, distributors, and independent sales representatives.
Curis, Inc. (NASDAQ: CRIS) is now covered by analysts at Oppenheimer. The analysts set an “outperform” rating and a $6.00 price target on the stock. Shares in CRIS are up 29.90% for the last 3 months.
CRIS, a drug discovery and development company, focuses on the research and development of cancer therapeutics. CRIS, under collaboration with Genentech, Inc., is conducting a pivotal Phase II clinical trial on its lead molecule, GDC-0449 in advanced basal cell carcinoma patients, as well as various Phase II clinical trials in first-line metastatic colorectal cancer and advanced ovarian cancer patients.
CRIS is also evaluating CUDC-101, a small molecule that is in a Phase I clinical testing and is designed to target histone deacetylase, epidermal growth factor receptor, and epidermal growth factor receptor 2. In addition, CRIS has a development candidate, Debio 0932, which is a Heat Shock Protein 90 or Hsp90 inhibitor.
CRIS holds a license agreement with Debiopharm related to its Hsp90 technologies. Further, it involves in preclinical testing for the development of candidates from its targeted cancer programs.Share